Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

AstraZeneca-Merck genetic disorder treatment wins FDA nod

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

The U.S. Food and Drug Administration approved a treatment developed by AstraZeneca Plc and Merck & Co Inc for a rare genetic disorder, the companies said on Tuesday.

Koselugo has been approved for treating paediatric patients two years of age and older with a form of neurofibromatosis, which is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Krishna Chandra Eluri)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.